Colgate-Palmolive (NYSE:CL) Stock Keeps Outperform Rating at BNP Paribas Exane

Colgate-Palmolive (NYSE:CL)‘s stock had its “outperform” rating reiterated by stock analysts at BNP Paribas Exane in a research note issued on Monday, Benzinga reports. They presently have a $108.00 price objective on the stock, up from their prior price objective of $97.00. BNP Paribas Exane‘s price objective would suggest a potential upside of 12.01% from the company’s previous close.

CL has been the topic of a number of other research reports. Raymond James Financial lifted their target price on Colgate-Palmolive from $100.00 to $102.00 and gave the company an “outperform” rating in a research report on Monday, August 3rd. Bank of America raised their price objective on Colgate-Palmolive from $100.00 to $105.00 and gave the company a “buy” rating in a report on Monday. Wells Fargo & Company boosted their target price on shares of Colgate-Palmolive from $90.00 to $95.00 and gave the stock an “equal weight” rating in a report on Monday. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Colgate-Palmolive in a research note on Thursday, August 13th. Finally, Morgan Stanley lifted their price target on shares of Colgate-Palmolive from $104.00 to $111.00 and gave the stock an “overweight” rating in a report on Monday. Thirteen equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $100.78.

Colgate-Palmolive Price Performance

Shares of NYSE CL traded up $1.13 during trading hours on Monday, hitting $96.42. 1,565,734 shares of the stock were exchanged, compared to its average volume of 5,625,901. The company’s fifty day simple moving average is $89.54 and its two-hundred day simple moving average is $89.65. The company has a market cap of $76.86 billion, a PE ratio of 37.77, a price-to-earnings-growth ratio of 4.59 and a beta of 0.31. The company has a debt-to-equity ratio of 13.82, a quick ratio of 0.30 and a current ratio of 0.46. Colgate-Palmolive has a 1-year low of $74.54 and a 1-year high of $99.33.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings data on Friday, October 30th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. Colgate-Palmolive had a net margin of 9.65% and a return on equity of 607.88%. The business had revenue of $5.37 billion during the quarter, compared to the consensus estimate of $5.34 billion. During the same period in the previous year, the business earned $0.91 earnings per share. The company’s revenue was up 4.6% on a year-over-year basis. On average, sell-side analysts predict that Colgate-Palmolive will post 3.89 EPS for the current year.

Insider Activity at Colgate-Palmolive

In other Colgate-Palmolive news, COO Panagiotis Tsourapas sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $92.05, for a total transaction of $920,500.00. Following the completion of the transaction, the chief operating officer owned 64,901 shares in the company, valued at approximately $5,974,137.05. This trade represents a 13.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Noel R. Wallace sold 161,021 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $91.92, for a total transaction of $14,801,050.32. Following the completion of the transaction, the chief executive officer owned 362,231 shares in the company, valued at $33,296,273.52. This trade represents a 30.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 175,191 shares of company stock worth $16,110,903 over the last ninety days. Insiders own 0.43% of the company’s stock.

Hedge Funds Weigh In On Colgate-Palmolive

A number of hedge funds have recently bought and sold shares of CL. Collaborative Fund Advisors LLC lifted its holdings in Colgate-Palmolive by 32.1% in the third quarter. Collaborative Fund Advisors LLC now owns 8,884 shares of the company’s stock valued at $758,000 after buying an additional 2,160 shares during the period. Chicago Partners Investment Group LLC grew its holdings in Colgate-Palmolive by 26.3% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 28,514 shares of the company’s stock worth $2,681,000 after acquiring an additional 5,940 shares during the period. Compass Financial Management LLC grew its stake in Colgate-Palmolive by 93.1% during the third quarter. Compass Financial Management LLC now owns 1,757 shares of the company’s stock worth $150,000 after purchasing an additional 847 shares during the period. Rakuten Investment Management Inc. grew its position in shares of Colgate-Palmolive by 9.3% during the 3rd quarter. Rakuten Investment Management Inc. now owns 140,679 shares of the company’s stock worth $12,163,000 after buying an additional 11,986 shares during the period. Finally, AIA Group Ltd increased its stake in shares of Colgate-Palmolive by 140.5% in the 3rd quarter. AIA Group Ltd now owns 47,369 shares of the company’s stock valued at $4,042,000 after acquiring an additional 27,670 shares in the last quarter. Institutional investors own 80.41% of the company’s stock.

Key Stories Impacting Colgate-Palmolive

Here are the key news stories impacting Colgate-Palmolive this week:

• Positive Sentiment: Better-than-expected quarterly results: Colgate-Palmolive reported third-quarter earnings of $0.97 per share, above the $0.93 consensus estimate, while revenue rose 4.6% year over year to $5.37 billion, slightly exceeding expectations. Colgate-Palmolive Analysts Boost Their Forecasts After Upbeat Q3 Earnings
• Positive Sentiment: Improved outlook: Management narrowed its 2026 sales outlook while raising its margin and earnings-per-share guidance, signaling improved confidence in profitability and supporting the positive market reaction. Colgate-Palmolive sales rise 4.6% and it lifts margin and EPS outlook
• Positive Sentiment: Analyst target increases: RBC raised its price target from $104 to $105 and maintained an “outperform” rating. Wells Fargo also increased its target from $90 to $95, despite retaining an “equal weight” rating.
• Neutral Sentiment: Mixed analyst signals: JPMorgan lowered its target from $104 to $102 but kept an “overweight” rating, while Barclays maintained a “hold” rating. These actions suggest continued confidence in the business but limited near-term upside at the current valuation.
• Negative Sentiment: Lingering profit concerns: Commentary following the earnings report noted that questions remain about profit growth, which could restrain further gains if cost pressures or weaker-than-expected margins emerge. Colgate Palmolive Stock Climbs After Q3 Earnings Yet Profit Questions Linger

About Colgate-Palmolive

Colgate-Palmolive Company (NYSE: CL) is a global consumer products company focused on oral care, personal care, home care and pet nutrition. Its portfolio includes toothpaste, toothbrushes, mouthwash, liquid hand soap, body wash, deodorants, household cleaning products and pet food and treats.

The company markets well-known brands such as Colgate, Palmolive, elmex, meridol, Softsoap, Irish Spring, Ajax, Protex and Hill’s Science Diet. Colgate-Palmolive also provides veterinary and nutritional products through Hill’s Pet Nutrition, which serves pet owners and animal health professionals.

Founded in 1806 by William Colgate, the company developed from a soap and candle business into a diversified consumer goods manufacturer.